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Deoxyribonucleic acid methylation is a long known epigenetic mark involved in many
biological processes and the ‘readers’ of this mark belong to several distinct protein
families that ‘read’ and ‘translate’ the methylation mark into a function. Methyl-CpG binding
domain proteins belong to one of these families that are associated with transcriptional
activation/repression, regulation of chromatin structure, pluripotency, development, and
differentiation. Discovered decades ago, the systematic determination of the genomic
binding sites of these readers and their epigenome make-up at a genome-wide level
revealed the tip of the functional iceberg. This review focuses on two members of the
methyl binding proteins, namely MBD2 and MBD3 that reside in very similar complexes,
yet appear to have very different biological roles.We provide a comprehensive comparison
of their genome-wide binding features and emerging roles in gene regulation.
Keywords: DNA methylation, methyl-CpG binding domain proteins, MBD2, MBD3, transcription regulation,
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INTRODUCTION
DNA METHYLATION
DNA methylation of cytosine residues was reported to be involved
in gene silencing as early as 1975 (Holliday and Pugh, 1975; Hol-
liday, 1989) and represents the ﬁrst epigenetic mark (Holliday,
1989). Inmammals, the predominant form is cytosinemethylation
(5mC) found within the context of paired symmetrical methyla-
tion at CpG dinucleotides. In mammalian genomes, around 70%
of CpG dinucleotides are methylated (Robertson and Jones, 2000),
however, CpG islands (CGIs) – regions of local high CpG den-
sity – are mainly unmethylated. CGIs constitute around 60% of
human promoters (Bird, 1986). Methylation of CGI promoters
results in transcriptional silencing, for example during genomic
imprinting and X-chromosome inactivation (Feinberg and Vogel-
stein, 1983; Ariel et al., 1995; Wutz et al., 1997). For many years,
DNA methylation has been regarded as long lasting and an epige-
netic lock on transcription. Cases of highly dynamic regulation
of DNA methylation were reported by the Gannon and Reid
laboratories (Kangaspeska et al., 2008; Metivier et al., 2008), sug-
gesting cyclical methylation/demethylation at promoters as a part
of the transcription cycle at least at some promoters. They showed
that the process involves DNA methyltransferases (DNMTs) as
well as thymine-DNA-glycosylase (Tdg). The recently discovered
active DNA-demethylation pathway involves ten-eleven translo-
cation (Tet) enzymes (Kriaucionis and Heintz, 2009; Tahiliani
et al., 2009; Cortellino et al., 2011). Tet enzymes catalyze conver-
sion of 5mC to 5-hydroxymethylcytosine (5hmC) and can further
oxidize 5hmC to 5-formylcytosine (5fC) and 5-carboxylcytosine
(5caC). Tdg can excise the latter two derivatives through base-
excision-repair process that will generate un-methylated cytosines
(Cortellino et al., 2011; He et al., 2011; Ito et al., 2011) closing the
methylation cycle. The breakthrough discovery that Tet enzymes
can oxidize 5-methylcytosine has revolutionized the concepts in
the epigenetic ﬁeld in general and the DNA methylation ﬁeld in
particular.
DNA-METHYLATION AND ITS READERS
The relationship between DNA methylation and transcriptional
silencing has proven challenging to decipher. Essentially, two types
of mechanisms have been put forward: in the ﬁrst a methylated
cytosine physically inhibits binding of transcriptional regulators.
Itwas reported that the binding of transcription factors such asAP-
2 (Comb and Goodman, 1990), c-Myc (Prendergast et al., 1991),
NF-kB (Bednarik et al., 1991), E2F1 (Kovesdi et al., 1987), and
CREB (Iguchi-Ariga and Schaffner, 1989), is affected by DNA
methylation.
The prevalent model proposes that proteins bind directly to
methylated DNA – the so-called readers – recruit co-repressor
complexes (Klose and Bird, 2006) and trigger the formation of
repressive chromatin. MethylatedDNA readers fall into threemain
classes: (i) proteins containing a methyl-CpG-binding domain
(MBD), (ii) Kaiso and Kaiso-like family of proteins including
ZBTB4-33-38, characterized by the presence of BTB/POZ domain
and several Kruppel-like C2H2 zinc ﬁngers, and (iii) SRA (SET
and RING ﬁnger associated) domain containing proteins, like
UHRF1 and UHRF2 characterized by the SRA domain that rec-
ognizes methylated DNA. Recently, a DNA pull-down screen
followed by Mass Spectrometry has uncovered additional 5mC
and 5hmC readers that do not belong to any of the three families
listed above (Spruijt et al., 2013), such as some homeobox and Rfx
proteins.
THE MBD FAMILY OF PROTEINS
The founding member of the MBD family is MeCP2 (Lewis et al.,
1992), a protein of 53 kDa containing an N-terminal MBD (Lewis
et al., 1992; Nan et al., 1993) and aC-terminal transcription repres-
sion domain (TRD; Nan et al., 1998). MeCP2 is ubiquitously
expressed and highly abundant in the brain. Mutations in the
gene encoding MeCP2 cause the Rett syndrome (Amir et al., 1999)
and other neurodevelopmental disorders (Moretti and Zoghbi,
2006). Crystal structure of the MBD domain, in complex with
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methylated DNA, showed that it binds symmetrical methylated
CpGs in vitro. The MBD domain of MeCP2 – a domain of 70
amino acids – has been used in homology searches that led to the
identiﬁcation of six additional family members named MBD1 to
MBD6 (Figure 1; Hendrich andBird,1998). Other studies revealed
four additional proteins that contain an MBD-like domain namely
SETDB1, SETDB2 (Schultz et al., 2002), BAZ2A andBAZ2B (Jones
et al., 2000).
MBD1, MBD2, and MBD4 can bind methylated DNA in vitro,
while MBD3, MBD5, and MBD6 do not appear to bind methy-
lated DNA, at least not in vitro (Laget et al., 2010). A recent study
on MBD5 and MBD6 revealed that their MBD domains interact
with the human PR-DUB complex (Baymaz et al., 2014). MBD1,
MBD2, MeCP2, and Kaiso appear not to be essential for develop-
ment since their deletion is not embryonic lethal whereas MBD3
plays an essential role in embryonic development (Hendrich et al.,
2001a; Martin Caballero et al., 2009).
MBD2 and MBD3 are close relatives and probably descend
via gene duplication from an ancestral MBD2/MBD3, that is
present in some metazoans as for instance Caenorhabditis ele-
gans and Drosophila (Marhold et al., 2004). Outside the MBD
domain, MBD2 and MBD3 share almost 80% homology; they
both have an MBD and a coiled-coil domain (CC). Apart from
this common domain, MBD2 contains an additional N-terminal
glycine-arginine (GR) rich domain and a transcriptional repressor
domain (TRD), whereas MBD3 has a C-terminal poly-glutamate
region. Three isoforms have been described for MBD2 protein:
the full length MBD2a, MBD2b lacking the N-terminal GR repeat
and MBD2c that is a testis speciﬁc isoform lacking the C-terminus.
AlsoMBD3presents three isoforms: Mbd3b– themajor isoform in
embryonic stem cells, Mbd3a and a smaller isoform Mbd3c (Kaji
et al., 2006). The crucial difference between MBD2 and MBD3 is
that MBD3 does not bind methylated DNA, because it lacks four
conserved amino acids in the MBD domain.
MBD PROTEIN COMPLEXES: LOOKING FOR FUNCTIONS
Biochemical data provided strong evidence that methyl-CpG-
binding domain proteins (MBPs) are an integral part of
chromatin-remodeling complexes reported to mediate hete-
rochromatin formation and transcriptional silencing. MeCP2
FIGURE 1 |The MBD family of proteins. Schematic overview of the
mammalian MBD family and their known domains (MBD,
methyl-CpG-binding domain; TRD, transcriptional repression domain; CXXC,
Zinc ﬁnger-Cys-x-x-Cys domain; G/R, arginine-rich; CC, coiled-coil; GLY,
glycosylase; PWWP, Pro-Trp-Trp-Pro).
transiently interacts with the Sin3A and HDAC2 complexes (Nan
et al., 1998), and MBD1 with SETDB1, SUV39H, and HP1 (Fujita
et al., 2003; Sarraf and Stancheva, 2004). MBD2 and MBD3 are
integral parts of the Mi-2/NuRD complex (Zhang et al., 1999;
Le Guezennec et al., 2006). Mi-2/NuRD complex is containing
ATP-driven chromatin remodeling and histone deacetylase activ-
ities. Protein interaction studies have demonstrated that MBD2
and MBD3 bind HDAC1/2 (Wade et al., 1999; Zhang et al., 1999),
GATAD2A (p66α) and GATAD2B (p66β; Brackertz et al., 2002;
Saito and Ishikawa, 2002; Gnanapragasam et al., 2011). Initially
MBD2 and MBD3 were thought to be part of the same com-
plex. It was postulated that Mi-2/NuRD containing both MBD2
and MBD3 is recruited to methylated DNA via MBD2 (Zhang
et al., 1999). Knockout studies however showed that MBD2 and
MBD3 have distinct functions because MBD3, but not MBD2,
is embryonic lethal (Hendrich et al., 2001b). Indeed biochemical
analyses showed that MBD3 and MBD2 are mutually exclusive
within the Mi-2/NuRD complex (Le Guezennec et al., 2006). In
addition to the already known Mi-2/NuRD components, DOC-
1 was identiﬁed as a novel subunit of both MBD2-NuRD (Le
Guezennec et al., 2006; Spruijt et al., 2010) and MBD3-NuRD
(Spruijt et al., 2013).
MBD PROTEINS IN TRANSCRIPTION REGULATION
The role of MBPs in transcription regulation has been widely
studied. MBPs have often been associated with transcriptional
repression because of their interaction with co-repressor com-
plexes triggering heterochromatin formation. However, a unifying
role and mechanism have yet to be established. Informative
approaches to decipher the function of a protein are knock-down
(KD), knock-out (KO), and overexpression studies. Surprisingly,
knock-down as well as overexpression of MeCP2 have been
reported to cause both transcription activation and repression
in the hypothalamus, with 85% of target genes being acti-
vated by MeCP2 (Chahrour et al., 2008). Also the KD of MBD2
resulted in both transcriptional activation and repression. For
instance it has been shown that in adult erythrocytes, MBD2
and MTA2 – a Mi-2/NuRD subunit – are enriched at the inac-
tive ρ-globin gene when this gene is highly methylated and
repressed. MBD2 KD resulted in re-expression of the ρ-globin
gene (Kransdorf et al., 2006). Another direct target of MBD2-
mediated repression is the Il4 gene, whose level of expression is
increased in T cells derived from Mbd2-null mice (Hutchins et al.,
2002). MBD2 was also reported to affect the Xist gene silencing
in mouse: Mbd2 knock-down cells display lower level reactivation
of Xist whereas silencing was rescued by re-expression of Mbd2
(Barr et al., 2007).
In a recent study, the link between MBD2 binding and
expression changes of neighboring genes was assessed using chro-
matin immunoprecipitation (ChIP) experiments followingMBD2
depletion (Günther et al., 2013). Only mild alterations in gene
expression were observed. Moreover, after MBD2 depletion, gene
expression changes revealed a roughly equal number of genes that
were up or down-regulated. As mentioned above, the level of DNA
methylation nor imprinting are affected in MBD2 null mice sug-
gesting that it is not required for correct silencing of imprinted
genes.
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Taken together, the generally accepted model of MBD2 acting
as a transcriptional repressor has not been unambiguously sup-
portedby experimental data and aunifyingmodel of themolecular
mechanism is missing.
MBD2 AND MBD3: THE COMPLEX BALANCE OF
PLURIPOTENCY/REPROGRAMMING
MBD2 has two isoforms: the full length MBD2a and a testis spe-
ciﬁc isoform MBD2c, lacking the C-term (Hendrich and Bird,
1998). The C-term domain of MBD2 is responsible for the inter-
action with p66α (GATAD2A) and therefore with the Mi2-NuRD
complex (Brackertz et al., 2002; Gnanapragasam et al., 2011). Pro-
tein interaction studies have shown that MBD2c is unable to bind
Mi-2/NuRD components such as Mi-2β, HDAC1 and HDAC2
(Baubec et al., 2013). A recent study showed that in human
pluripotent stem cells the two isoforms sustain different pathways:
MBD2a promotes differentiation and its overexpression disrupts
pluripotency while MBD2c facilitates reprogramming of ﬁbrob-
lasts (Lu et al., 2014). Moreover this study shows that the 3′ UTR
of MBD2a is a direct target of the miR-302, previously reported
to promote reprogramming (Subramanyam et al., 2011) via up-
regulation of NANOG expression and suppression of MBD2 (Lee
et al., 2013). These recent ﬁndings shed new light on the role of
MBD2 in regulating the commitment toward either reprogram-
ming or differentiation, involving the microRNA and splicing
factors. Further analysis will be needed to dissect the transcrip-
tional and epigenetic changes in response to deletion of either
isoforms, in order to identify speciﬁc targets and downstream
effectors that might be mediating either lineage commitment or
retention of pluripotency.
The role of MBD3 in lineage commitment and pluripotency
has recently been at the focus of attention (Yildirim et al., 2011;
Reynolds et al., 2012; Whyte et al., 2012). The importance of
MBD3 in regulating escape from pluripotency and lineage com-
mitment has been documented in several studies. Early reports
described Mbd3 as essential for lineage commitment, since Mbd3
depleted mouse embryonic stem cell failed to differentiate and
aberrantly self-renewed independently of leukemia inhibitory
factor (LIF), one of the essential factors needed to keep undif-
ferentiated stem cells in culture (Kaji et al., 2006). Recently two
independent studies showed that Mbd3 constitutes a gate to full
reprogramming and that its depletion together with transduction
of the four Yamanaka factors (Oct4, Sox2, Klf4, Myc, all together
OSKM) enhances the reprogramming efﬁciency, consistent with
the role of Mbd3 as suppressor of reprogramming (Luo et al., 2013;
Rais et al., 2013). However, other ﬁndings suggest an opposite role
for Mbd3 in facilitating induction of pluripotency (Dos Santos
et al., 2014). The authors themselves underline that the differences
with respect to previous studies might be due to a different cell sys-
tem and reprogramming conditions, and that their ﬁndings may
be context speciﬁc. However, reproducibility of previous results
seemed to be somewhat challenging, raising more questions than
providing answers.
MBPs IN THE ORGANIZATION OF CHROMATIN STRUCTURE
Several studies have pointed to a role of MBD proteins in the orga-
nization of chromatin structure and shaping the local and global
epigenome landscape, for instance formation or maintenance of
heterochromatic, repressive chromatin (Clouaire and Stancheva,
2008; Fournier et al., 2012), given the presence of an ATP-driven
remodeler subunit within the Mi-2/NuRD complex (Wade et al.,
1999; Zhang et al., 1999).
Little is known about the impact of MBD2 on chro-
matin organization in vivo. It has been observed that mouse
myoblasts undergoing myogenic differentiation form aggregates
of pericentric heterochromatin (chromatin surrounding the
centromere) that display increased levels of MeCP2, MBD2,
and DNA methylation (Brero et al., 2005; Luo et al., 2009).
Overexpression of MBD2 or for that matter MeCP2 induced
condensation of densely stained heterochromatin within the
nucleus. Interestingly also in the absence of MeCP2 (skeletal
muscle tissue derived from MeCP2 knock-out mice), MBD2
overexpression triggered the formation of densely stained
repressive chromatin, suggesting some degree of functional
redundancy or overlap. The molecular mechanisms behind
this aggregation of pericentric chromatin remain unclear. A
recent study shows that in human cells ectopic expression of
MBD2, but not MBD3, induces heterochromatin compaction
(Günther et al., 2013). To resolve the putative role of MBD2 in
the formation of higher order chromatin structure it will be
important to combine genome-wide localization studies with
chromosome conformation capture approaches. A ﬁrst study
along these lines (Shimbo et al., 2013) indeed suggests that
MBD3 binding to enhancers results in their closer proxim-
ity to promoters and gene bodies because of protein mediated
looping.
FIGURE 2 | MBD2 binding to chromatin. (A) Schematic representation of
MBD2 binding to highly methylated CGI promoters (B) MBD2 binding to
highly methylated CGI exons. (C) Subset of MBD2 binds to un-methylated
active promoters, this binding depends on the interaction with Mi-2/NuRD
complex that might be recruited to chromatin via other, not yet identiﬁed
factors.
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GENOME-WIDE MBD2 AND MBD3 BINDING SITE ANALYSES
Chromatin immunoprecipitation followed by next generation
sequencing, (ChIP-seq) is widely used to determine the bind-
ing sites of a protein or transcription factor in a genome-
wide manner. A substantial amount of literature describes the
characterization of MBD2 and MBD3 binding to chromatin
at speciﬁc loci but only recent studies provided genome-wide
maps. ChIP experiments on chromatin regulators, such as
Mi-2/NuRD complex, turned out to be quite challenging, pre-
sumably because of a combination of factors: low abundancy
of the proteins, the transient nature of the chromatin associa-
tion, short residence time on chromatin and the quality of the
antibodies.
Recent genome-wide mapping of MBPs has clearly shown that
MBD2 binds to highly methylated, CpG dense regions in vivo
(Baubec et al., 2013). Interestingly, motif analysis did not reveal
any speciﬁc DNA sequence motif within the MBD2 binding
sites and their ﬂanking regions, but highlighted primarily CG
richness of the binding sites as the critical factor for binding.
In line with this, an intact methyl binding domain is essential
to target MBD2 to densely methylated loci. DNA methylation
is a prerequisite since binding of MBD2 is lost in cells with
triple knock-out for Dnmt1-3a/b, that lack both methylation and
hydroxymethylation. MBD2 primarly binds at highly methylated
promoters (Günther et al., 2013; Menafra et al., 2014) and sec-
ondly exons (Figures 2A,B). Surprisingly, in mouse embryonic
stem cells, a correlation between genome-wide MBD2 binding
and known components of the Mi-2/NuRD complex such as
Mi-2β and Hdac2 was not observed. It should be noted how-
ever that the proﬁles for the two subunits were not performed
in parallel (Whyte et al., 2012). Interestingly, a subset of MBD2
binding sites have been uncovered that did not have DNA methy-
lation. The presence of MBD2 at these loci was suggested to
be due to its association with the Mi-2/NuRD complex that
was recruited to chromatin via other, not yet identiﬁed factors
(Figure 2C). Indeed, MBD2 binding at such loci was lost when
the testis speciﬁc MBD2 isoform was expressed that lacks the
C-terminus and does not immunoprecipitate any of the known
Mi-2/NuRD components. Surprisingly, Baubec et al. also found
that MBD2 is recruited to a subset of un-methylated loci that
displayed epigenetic marks pointing at active regulatory regions.
These data were conﬁrmed in another independent study in
which a tagged MBD2 was expressed in human MCF-7 cells. A
small fraction of MBD2 binding sites was observed at promoters
of genes displaying active histone marks and low gene expres-
sion (Menafra et al., 2014). Interestingly, the study from Günther
et al. revealed a dichotomy within MBD2 binding to promoters
of silent genes and at the same time to exons of actively tran-
scribed genes, suggesting that in the latter case, MBD2 might
play a role in splicing. It remains to be elucidated what the
effects of MBD2 binding are on transcription and chromatin
organization.
Table 1 | Summary of studies characterizing MBD3 binding genome-wide: technical details of the experiments together with findings and
algorithm used for the analysis are listed.
Study Organism Cell
type
Insert Antibody Localization Chromatin features Number of
peaks/enriched
regions
Algorithm
used for
analysis
Yildirim et al.
(2011)
Mouse ES NA
(endogenous)
Mix of
(ab3755) and
Bethyl
(A302-528A)
Downstream
TSS
Hydroxy-methyl, Tet1 NA NA
Baubec et al.
(2013)
Mouse ES MBD3
biotinylated
Streptavidin
beads
Unmethylated
regions
DNaseI, H3K4me1,
and H3K27ac
NA Enrichment
over input in a
1 kb sliding
window
Günther et al.
(2013)
Human HeLa MBD3-V5 V5 agarose
(Sigma Aldrich
A7345)
CpG rich,
unmethylated
promoters
H3K4me2/3; H3K9ac;
DNAse1; FAIRE
490 Peak-ranger
Shimbo et al.
(2013)
Human MCF-7 NA
(endogenous)
Ab91458 Promoters,
gene bodies
and enhancers
of active genes
Five patterns:mainly
H3K27ac (not TSS)
and H3K4me3TSS
35165 SICER
Shimbo et al.
(2013)
Human MDA-
231
NA
(endogenous)
Ab91458 Promoters,
gene bodies
and enhancers
of active genes
Five patterns:mainly
H3K27ac (not TSS)
and H3K4me3TSS
23880 SICER
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Identiﬁcation of genome-wide binding sites and functional
analyses of MBD3 have been performed in mouse (Yildirim et al.,
2011; Baubec et al., 2013) and human cells (Günther et al., 2013;
Shimbo et al., 2013) reaching different conclusions. Yildirim et al.
reported that MBD3 binds just downstream of the transcription
start site (TSS) of CpG-rich promoters marked by hydroxymethy-
lation. Baubec et al. found, however, that MBD3 binds to active
regulatory regions (enhancers) independent of CpG density and
independent of their methylation or hydroxymethylation status,
since binding was maintained in Dnmt1/3a/3b triple knock-out
embryonic stem cells. These data question the validity of the
binding of MBD3 to hydroxymethylated DNA, which was further
underpinned byDNApull-downs followed byMS analysis (Spruijt
et al., 2013), which did reveal hydroxymethylation speciﬁc readers
but in which MBD3 was not detected.
Independent studies in human cells (Günther et al., 2013;
Shimbo et al., 2013) both suggested that MBD3 is localized at
CpG rich promoters of active genes, but while Günther et al.
(2013) showed that it mainly binds promoters, Shimbo and
coworkers suggested a more complex regulation of both active
and silent genes. They showed that a fraction of MBD3 binds
at enhancers that are in physical proximity to promoters and
gene bodies in three-dimensional space and hence are picked up
in the assay. Since these data have been generated by different
groups, using different antibodies, cell systems, and sequencing
analysis pipelines (see Table 1, for a summary of the differ-
ent studies), re-analysis of the data with a common approach
may resolve some of the major and minor discrepancies. Inter-
estingly, the genome-wide binding map of MBD3 correlates to
some extend with that of another Mi-2/NuRD component, Mi-
2β, implying partial co-recruitment of these two subunits on
chromatin. Further studies will be needed to assess whether this
interaction is necessary for Mi-2/NuRD to bind the chromatin and
whether MBD3 depletion would result in loss of Mi-2β binding
or vice versa. Similarly as reported for MBD2, depletion of MBD3
in human (Günther et al., 2013) and mouse cells (Yildirim et al.,
2011) resulted in alteration of gene expression for only a small
number of genes and in both cases, the transcriptional changes
are rather mild.
Taken together, the above ﬁndings suggest that MBD3 binds
CpG-rich active promoters and enhancers that are not DNA
methylated (Figure 3). The downstream functional consequence
of MBD3 binding has still to be elucidated.
CONCLUDING REMARKS
Since its discovery in 1975, DNA methylation has been one of the
best studied epigenetic marks and the readers of DNA methyla-
tion that translate the signal of methylated DNA into a function
or activity have obtained a lot of attention. MBD2 and MBD3
are two very similar proteins, which are interchangeable struc-
tural parts of the Mi-2/NuRD complex and share many common
subunits. Nevertheless, they appear to perform distinct functions
and to differ completely in their ability to bind methylated DNA.
The emerging picture is that MBD2 binds to CpG-rich, densely
methylated DNA in vivo, with an apparent but not understood
preference for promoter regions. A minor fraction of MBD2 is
present at promoters that bear active epigenetic marks and are not
FIGURE 3 | MBD3 binding to chromatin. (A) Schematic representation of
MBD3 binding to unmethylated CGI promoters (B) MBD3 binding to
unmethylated enhancers, that are in physical proximity to promoters in
three-dimensional space. The question mark indicates the possible
presence of other subunits involved in this association.
methylated. This is the only fraction of binding sites depending
on the interaction with Mi-2/NuRD, suggesting that MBD2 might
also have a function independent of Mi-2/NuRD. Recruitment of
Mi-2/NuRD might also depend on subunits other than MBD2
such as GATAD2A-B or MTA1-2 that is reported to directly bind
the histone H3 tail in vitro (Robertson and Jones, 2000; Wu et al.,
2013). Supporting in vivo data is currently not available. There-
fore additional biochemical studies followed by in vivo evidence,
for example by ChIP-seq, should be performed to assess whether
MBD2 exists in distinct complexes and can bind to unmethy-
lated regions independent of Mi-2/NuRD. MBD3 binds CpG-rich,
unmethylated active promoters and enhancers. One of the burning
questions is how MBD3/NuRD is recruited to its genomic binding
sites. Does MBD3 play a role, are other subunits important or is
the association based on transient protein-mediated interactions?
What seems clear is that MBD3 plays an important role in lineage
commitment.
The biological functions of MBD2 and MBD3 remain an open
question; whether and how they modulate transcriptional activity
and chromatin structure. The recent coupling of chromosome
conformation capture technologies with deep-sequencing might
provide an interesting angle to look for possible participation of
MBD2 in long range interactions, amodel proposed forMBD3but
not yet addressed in a genome-wide fashion. Even after decades
of research, DNA methylation readers are still hiding their true
nature, raising puzzling but at the same time intriguing questions
for further research.
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